The Otsuka Pharmaceutical and Click Therapeutics mobile app Rejoyn received FDA clearance for use as an adjunct to medication in the treatment of major depressive disorder. But Otsuka must overcome hurdles facing digital therapeutics products, which have yet to gain traction among payers.
Digital therapeutics developer Click Therapeutics is partnering with Indivior to develop a mobile app for substance use disorder. Indivior is now Clickâs third development partner, following deals with Boehringer Ingelheim and Otsuka Pharmaceutical.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Click Therapeutics is developing digital therapeutics for depression, insomnia and other conditions. It plans to use the funds to commercialize its therapeutics, through partnerships with pharmaceutical companies including Otsuka.
Otsuka Pharmaceutical is partnering with Click Therapeutics to launch a remote clinical trial to evaluate the effectiveness of digital therapeutics in reducing depressive symptoms.
Otsuka's top U.S.-based leaders spoke about the company's partnerships in mental health and how it is driving innovation in big pharma.
In 2018 alone, ten companies have inked mega-deals of more than $100 million including Livongo, 23andMe and American Well.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.